NAFLD

Metabolic Diseases
5
Pipeline Programs
11
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Vedanta Biosciences
Vedanta BiosciencesMA - Cambridge
1 program
1
Gut microbiome transplantationPhase 41 trial
Active Trials
NCT04465032Unknown20Est. Dec 2021
Neuraly
NeuralyMD - Gaithersburg
1 program
1
DD01Phase 21 trial
Active Trials
NCT06410924Active Not RecruitingEst. Jun 2026
Ipsen
IpsenChina - Tianjin
1 program
1
ElobixibatPhase 21 trial
Active Trials
NCT04006145Completed47Est. Jul 2020
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
Semaglutide Pen InjectorPhase 2Peptide1 trial
Active Trials
NCT05424003Recruiting50Est. Feb 2026
Bristol Myers Squibb
1 program
1
BMS-986036Phase 11 trial
Active Trials
NCT03674476Completed40Est. Jun 2019
Pfizer
PfizerNEW YORK, NY
1 program
Follow-upN/A1 trial
Active Trials
NCT05971082Unknown1,000Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vedanta BiosciencesGut microbiome transplantation
NeuralyDD01
Novo NordiskSemaglutide Pen Injector
IpsenElobixibat
Bristol Myers SquibbBMS-986036
PfizerFollow-up

Clinical Trials (6)

Total enrollment: 1,157 patients across 6 trials

NCT04465032Vedanta BiosciencesGut microbiome transplantation

The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)

Start: Dec 2019Est. completion: Dec 202120 patients
Phase 4Unknown

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Start: Jun 2024Est. completion: Jun 2026
Phase 2Active Not Recruiting
NCT05424003Novo NordiskSemaglutide Pen Injector

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Start: Feb 2024Est. completion: Feb 202650 patients
Phase 2Recruiting

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Start: Jun 2019Est. completion: Jul 202047 patients
Phase 2Completed

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Start: Sep 2018Est. completion: Jun 201940 patients
Phase 1Completed

Risk Factors for Advanced Fibrosis Among FLD Patients

Start: Aug 2023Est. completion: Dec 20251,000 patients
N/AUnknown

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,157 patients
11 companies competing in this space